Angiotensin type 2 receptor in hypertensive cardiovascular disease.

作者: Carmine Savoia , Michela DʼAgostino , Francesco Lauri , Massimo Volpe

DOI: 10.1097/MNH.0B013E3283437FCD

关键词:

摘要: Purpose of review The renin angiotensin system plays a key role in the development hypertension-induced cardiovascular remodeling and damage. Angiotensin II (Ang II) exerts its effects by acting on two distinct subtypes receptor, type 1 receptor (AT1R) 2 (AT2R). Whereas AT1R mediates most recognized actions Ang II, it appears that AT2R opposes, part, mediated AT1R. As is expressed adult tissues smaller numbers than AT1R, cell signaling have been less well characterized those Recent findings Current knowledge suggests stimulation vasodilation, antigrowth, proapoptotic antiinflammatory effects. Hence, can modulate as progression atherosclerosis. A protective has also documented humans, mainly during chronic inhibition. Furthermore, new nonpeptide agonist developed, with potential future therapeutic applications hypertensive conditions. Summary This article reviews expression function pathogenesis functional structural alterations induced hypertension system.

参考文章(100)
S Bosnyak, IK Welungoda, A Hallberg, M Alterman, RE Widdop, ES Jones, Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats British Journal of Pharmacology. ,vol. 159, pp. 709- 716 ,(2010) , 10.1111/J.1476-5381.2009.00575.X
Katarina BEDECS, Nathalie ELBAZ, Malène SUTREN, Maryline MASSON, Christiane SUSINI, A. Donny STROSBERG, Clara NAHMIAS, Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochemical Journal. ,vol. 325, pp. 449- 454 ,(1997) , 10.1042/BJ3250449
J. D. Catravas, A. Chester, K. Morgan, J. Wharton, J. M. Polak, B. F. Whitehead, M. H. Yacoub, M. R. De Leval, R. A. D. Rutherford, DIFFERENTIAL DISTRIBUTION OF ANGIOTENSIN AT2 RECEPTORS IN THE NORMAL AND FAILING HUMAN HEART Journal of Pharmacology and Experimental Therapeutics. ,vol. 284, pp. 323- 336 ,(1998)
Peter Zahradka, Lorraine Yau, Chantal Lalonde, John Buchko, Shawn Thomas, Julieta Werner, Mirei Nguyen, Laura Saward, Modulation of the vascular smooth muscle angiotensin subtype 2 (AT2) receptor by angiotensin II Biochemical and Biophysical Research Communications. ,vol. 252, pp. 476- 480 ,(1998) , 10.1006/BBRC.1998.9669
Hiroaki Matsubara, Takeshi Sugaya, Satoshi Murasawa, Yoshihisa Nozawa, Yasukiyo Mori, Hiroya Masaki, Katsuya Maruyama, Yoshiaki Tsutumi, Yasunobu Shibasaki, Yasutaka Moriguchi, Yohko Tanaka, Toshiji Iwasaka, Mitsuo Inada, Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron. ,vol. 80, pp. 25- 34 ,(1998) , 10.1159/000045121
Mohan Viswanathan, Keisuke Tsutsumi, Fernando M.A. Correa, Juan M. Saavedra, Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochemical and Biophysical Research Communications. ,vol. 179, pp. 1361- 1367 ,(1991) , 10.1016/0006-291X(91)91723-P
Massimo Volpe, Beatrice Musumeci, Paola De Paolis, Carmine Savoia, Alberto Morganti, Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? Journal of Hypertension. ,vol. 21, pp. 1429- 1443 ,(2003) , 10.1097/00004872-200308000-00001
I Makino, K Shibata, Y Ohgami, M Fujiwara, T Furukawa, Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides. ,vol. 30, pp. 596- 601 ,(1996) , 10.1016/S0143-4179(96)90043-8
H Rogg, M De Gasparo, E Graedel, P Stulz, F Burkart, M Eberhard, P Erne, None, Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction European Heart Journal. ,vol. 17, pp. 1112- 1120 ,(1996) , 10.1093/OXFORDJOURNALS.EURHEARTJ.A015008
Carmine Savoia, Ernesto L. Schiffrin, Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions Clinical Science. ,vol. 112, pp. 375- 384 ,(2007) , 10.1042/CS20060247